[1] Wild CP, Weiderpass E, Stewart BW. World
Cancer Report: Cancer Research for Cancer Prevention[R].WHO, 2020.
[2] Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance
to cancer therapies[J]. Nat Rev Clin Oncol, 2018,15(2): 81-94.
[3] Wahida A, Buschhorn L, Fröhling S, et al. The coming decade in precision oncology: six riddles[J]. Nat Rev Cancer, 2023, 23(1): 43-54.
[4] Lee H, Martinez-Agosto JA, Rexach J,et al. Next generation sequencing in clinical diagnosis[J]. Lancet Neurol,2019, 18(5): 426.
[5] 中国初级卫生保健基金会肿瘤精准诊疗专业委员会,
中国抗癌协会肿瘤精准治疗专业委员会,
中国抗癌协会肿瘤病理专委会肺癌学组. 基于RNA-based NGS检测非小细胞肺癌融合基因临床实践中国专家共识
[J]. 中国肺癌杂志, 2023,26(11):801-812.
[6] Cui J, Jiao F, Li Q, et al. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and
treatment of pancreatic cancer[J]. Journal of the National Cancer Center, 2022, 2(4): 205-215.
[7] Sunami K, Takahashi H, Tsuchihara K, et al. Clinical practice guidance for next‐generation sequencing in
cancer diagnosis and treatment (Edition 1.0) [J]. Cancer Sci, 109(9): 2980-2985.
[8] Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a
report from the ESMO Precision Medicine Working Group[J]. Ann Oncol, 31(11): 1491-1505.
[9] Cancer Genome Atlas Research
Network, Weinstein JN, Collisson EA,et al. The Cancer Genome Atlas Pan-Cancer analysis project[J]. Nat Genet, 2013. 45(10): 1113-1120.
[10] International Cancer Genome
Consortium, Hudson TJ, Anderson W, et al. International network of cancer genome
projects[J]. Nature, 2010, 464(7291): 993-998.
[11] Raufaste-Cazavieille V, Santiago R, Droit A. Multi-omics analysis: Paving the path toward
achieving precision medicine in cancer treatment and immuno-oncology[J]. Front Mol Biosci, 2022, 9: 962743.
[12] Worst BC, van Tilburg CM, Balasubramanian GP, et al. Next-generation personalised medicine for high-risk paediatric cancer patients—The INFORM pilot study[J]. Eur J Cancer, 2016, 65: 91-101.
[13] van Tilburg CM, Witt R, Heiss M, et al. INFORM2 NivEnt: The first trial of the
INFORM2 biomarker driven phase I/II trial series: the
combination of nivolumab and entinostat in children and adolescents with
refractory high-risk malignancies[J]. BMC Cancer, 2020, 20(1): 523.
[14] Horak P, Klink B, Heining C, et al. Precision oncology based on omics data: The NCT Heidelberg experience[J]. Int J Cancer, 2017, 141(5): 877-886.
[15] Tamborero D, Dienstmann R, Rachid MH, et al. The Molecular Tumor Board Portal supports clinical decisions
and automated reporting for precision oncology[J]. Nat Cancer, 3(2): 251-261.
[16] Kumar S, Warrell J, Li S, et al. Passenger mutations in more than 2500 cancer genomes: overall molecular functional impact and consequences[J]. Cell, 2020, 180(5): 915-927.
[17] Arnaud M, Chiffelle J, Genolet R, et al. Sensitive identification of neoantigens and cognate TCRs in
human solid tumors[J]. Nat Biotechnol, 2022, 40(5):656-660.
|